Genomed (WAR:GEN) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GEN Genomed SA WAR:GEN
88 GF Score
Price zł30.80
GF Value zł38.40
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomed Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

WAR:GEN vs TMO, DHR, IDXX: Short Interest Comparison

For the Diagnostics & Research subindustry, Genomed's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomed Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Short Interest distribution charts can be found below:

* The bar in red indicates where Genomed's Short Interest falls into.


WAR:GEN
88GF Score
Genomed SA WAR:GEN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł30.80 is trading 19.8% below its estimated GF Value™ of zł38.40. GuruFocus considers Genomed to be Modestly Undervalued.

Key valuation signals for WAR:GEN:

  • Short Interest:
  • GF Value™: zł38.40 vs. price of zł30.80 (19.8% below fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
88GF Score

Get the complete analysis for WAR:GEN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł30.80
Price
zł38.40
GF Value